An mrna multivalent approach including pre-erythrocytic-stage antigens and mosquito saliva antigens to broaden the immune targets against malaria infection

Ended Cooperative Agreement Awarded Last action

Award ID
HT94252320024
Recipient
Awarding agency
Obligated
$638,820

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Tacoma, WA 98402, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

This Cooperative Agreement award of $638,820 from the Defense Health Agency supports an mRNA multivalent approach to develop an innovative malaria vaccine. The project, funded through the Military Medical Research and Development program (CFDA 12.420), aims to broaden the immune targets against malaria infection by including both pre-erythrocytic-stage antigens and mosquito saliva antigens. The Geneva Foundation, a non-profit research organization, will conduct this research over a 3-year period from September 2023 to September 2026. This project represents a partnership between the U.S. government and a specialized medical research institution to address a critical military healthcare priority through advanced biomedical research and development.

Quick answers

Who received award HT94252320024?

HT94252320024 was awarded to The Geneva Foundation by Defense Health Agency (Department of Defense) on September 30, 2023.

How much is award HT94252320024 worth?

$638,820 has been obligated on HT94252320024.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login